Stage IIIA-N2 NSCLC: a review of its treatment approaches and future developments

Jan P van Meerbeeck; Veerle F M Surmont

doi:10.1016/j.lungcan.2009.02.007

Stage IIIA-N2 NSCLC: a review of its treatment approaches and future developments

Lung Cancer. 2009 Sep;65(3):257-67. doi: 10.1016/j.lungcan.2009.02.007. Epub 2009 Mar 13.

Authors

Jan P van Meerbeeck¹, Veerle F M Surmont

Affiliation

¹ Department of Respiratory Medicine & Thoracic Oncology, University Hospital, Ghent, Belgium. [email protected]

PMID: 19285751
DOI: 10.1016/j.lungcan.2009.02.007

Abstract

Few issues are as controversial in non-small cell lung cancer as the management of patients with stage IIIA-N2 non-small cell lung cancer. This manuscript reviews the reasons and the biases inherent to this controversy and discusses the different treatment approaches with emphasis on survival as evidenced by meta-analyses and large randomised clinical trials. Prospects on novel treatment modalities and future research opportunities are presented.

Publication types

Review

MeSH terms

Carcinoma, Non-Small-Cell Lung / mortality
Carcinoma, Non-Small-Cell Lung / pathology
Carcinoma, Non-Small-Cell Lung / surgery
Carcinoma, Non-Small-Cell Lung / therapy*
Combined Modality Therapy / trends
Drug Therapy / trends
Guidelines as Topic
Humans
Lung Neoplasms / mortality
Lung Neoplasms / pathology
Lung Neoplasms / surgery
Lung Neoplasms / therapy*
Meta-Analysis as Topic
Neoplasm Staging
Radiotherapy / trends
Randomized Controlled Trials as Topic
Survival Analysis